Navigation Links
New Anti-Clotting Drug Shows Promise in Heart Patients
Date:11/4/2007

Prasugrel reduced heart risks after angioplasty/stenting, but raised bleeding risks when compared to Plavix

SUNDAY, Nov. 4 (HealthDay News) -- A new anti-clotting drug might one day challenge Plavix, the current standard of therapy for people who have undergone procedures to open blocked coronary arteries, a new study suggests.

But a sizable subset of the heart patients studied -- notably those who had had a prior stroke, were elderly, or had a low body weight -- faced a significantly higher risk of potentially fatal bleeding on the new drug, known as prasugrel.

Experts said it's hard to tell whether prasugrel will replace Plavix as the first medication doctors turn to after angioplasty and stenting when trying to reduce the chances of clotting and its attendant risks, which include heart attack and stroke.

"This is not an FDA-approved drug," Dr. Dan Jones, president of the American Heart Association (AHA), said Sunday during a news conference at the AHA's annual meeting in Orlando. "Many of the questions today had to do with whether this data will be sufficient for FDA approval, and I just don't know."

The trial, funded by Daiichi Sankyo Co. Ltd. and Eli Lilly & Co., will also be published in the Nov. 15 issue of the New England Journal of Medicine.

To see if the standard therapy could be improved, researchers randomly chose 13,608 patients at 707 sites in 30 countries to receive either prasugrel (60 milligrams as a one-time "loading" dose, followed by a 10-milligram maintenance dose) or Plavix (300 milligrams initially, followed by a daily 75-milligram maintenance dose) for up to 15 months following angioplasty and stenting to open blocked arteries.

"We sought to test whether a regimen that is associated with higher degrees of inhibition of platelet aggregation, meaning it inhibits the ability of platelets to clot more effectively, would reduce events in patients undergo
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. FDA Approves New Anti-Clotting Drug
2. Aspirin surpasses Modern Anti-clotting Drugs
3. Enduring anti-clotting treatment avails heart patients
4. New Anti-Clotting Drug Less Risky For Heart Attack Patients
5. Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions
6. Warfarin’s Anti-clotting Property May Cause Hemorrhagic Stroke
7. Experimental treatment for Ebola Virus Shows promising results in mice
8. Gene Therapy shows promise in treating Hemophilia
9. New Prostate Cancer Vaccine Shows Promise
10. Leukemia pill shows promise against stomach cancer
11. Stent shows promise in keeping arteries open
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Anti-Clotting Drug Shows Promise in Heart Patients
(Date:5/24/2013)... hospitalized for heart failure appear to have better odds ... the morning, a new study finds. Death rates ... patients admitted in January, on Fridays and overnight, according ... findings Saturday in Portugal at the annual meeting of ... Cardiology. "The fact that patients admitted right ...
(Date:5/24/2013)... The Mirena IUD lawyers at the Rottenstein ... has received more than 59,229 complaints since 2004 from women ... control device known as the Mirena IUD.* , Among the ... women “included ‘expulsion,’ where the IUD came out on its ... an ABC News article. “Abdominal pain is also common, with ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Drugs commonly used ... side effects that can interfere with vision, according to ... analogues (PGAs), which are used to reduce eye pressure, ... and changes in eye color, the researchers said, suggesting ... for PGAs. Doctors should be conservative when ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV ... consumers compare the features and services offered by ... released the rankings of the best rural ... viewing on their website. , BestSatelliteProviders.com ... Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers ...
Breaking Medicine News(10 mins):Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... 24 Bridy Condon of the,Pollakov Financial Group ... Massachusetts,Mutual Life Insurance Co. (MassMutual), is the recipient ... remarkable service to her client, a,widow suffering from ... realLIFEstories Client Service Award, which,recognizes insurance professionals whose ...
... Under New Corporate Identity, NEW YORK ... an,established pharmaceutical analytics company, today introduces its ... growth the,Company has achieved across its full ... tailor the advertising and marketing programs,of its ...
... ANGELES, Sept. 24 The founder of the Deane ... and its,co-founder and medical director, Dr. Jeffrey L. Cummings, ... center celebrates its 3rd anniversary,with a reception at 5:30pm ... Campus. "The Deane Team" will be a mobile ...
... Medical Technologies,and Stille AB (listed at First North ... into a strategic marketing and distribution partnership.,Beginning in ... Enova,s,breakthrough LED cordless headlights to the surgical market ... and, on a non-exclusive,basis, throughout the rest of ...
... Wake Forest University Baptist Medical Center and colleagues suggest ... rare tightening and swelling of the skin and other ... in the October issue of the American Journal of ... some patients on kidney dialysis who are injected with ...
... The New Jersey,Hospital Association,s Health Research and Educational ... Mindy Melina Michel of Jackson,Tonya Jones of Eatontown, ... Ridge. Since 1983, HRET has awarded health ... New Jersey residents to pursue health careers. More ...
Cached Medicine News:Health News:MassMutual Agent Honored by Insurance Industry for Extraordinary Service to Client 2Health News:Eularis Announces New Corporate Name and Expanded Product Offerings 2Health News:Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th 2Health News:Stille and Enova Form Strategic Partnership to Introduce World's Brightest LED Cordless Surgical Headlights Into Europe and Japan 2Health News:New study suggests cause of debilitating skin condition 2Health News:HRET Awards Four Health Career Scholarships 2
(Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Northern Ireland , August 2, 2010 Almac today,announced ... solutions,specifically designed to meet the needs of the biopharma industry. , ... ... adopting,biomarker strategies to enable them to better understand their drug, improve,their ...
... , July 30 Anadys Pharmaceuticals, Inc. (Nasdaq: ... BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, ... a.m. PDT ).  The conference is being held at the Sheraton New ... of Anadys, will provide an overview of Anadys and its clinical development ...
Cached Medicine Technology:Almac Launch Biomarkers for Biopharma 2Almac Launch Biomarkers for Biopharma 3Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference 2
... innovative capillary electrophoresis system is designed ... testing. The CAPILLARYS 2 utilizes liquid ... clinical diagnostic setting. Through continuous sample ... very narrow capillary tubes functioning concurrently, ...
... These unique Acid Fast Control ... smear with appropriate background material. ... a positive and negative smear. ... (Cat. No. 353), Ziehl-Neelsen or ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Medicine Products: